+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 12Years - 70Years
All Genders
ID07499544

Multicenter Randomized Trial Evaluating Libevitug Injection for Chronic Hepatitis Delta Virus Infection Phase III Open-Label Study of Libevitug Safety and Efficacy

Led by Huahui Health · Updated on 2026-08-24

160

Participants Needed

7

Research Sites

72 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting an international, multicenter, randomized, controlled, open-label Phase III trial to evaluate the effectiveness and safety of libevitug in people with chronic Hepatitis Delta Virus HDV infection. The study focuses on participants aged 12 to 70 years who have a history of chronic HDV infection and specific liver enzyme levels. Participants will be assigned to one of three groups one group receiving libevitug at 20 mgkg every two weeks through intravenous infusion for 96 weeks another group receiving a lower dose of 10 mgkg on the same schedule and a control group observed for 48 weeks before then receiving the 20 mgkg libevitug dosage for the following 48 weeks. This setup allows comparison of different dosing and delayed treatment effects. Throughout the study, participants will undergo regular evaluations including liver function tests, viral load measurements, and liver stiffness assessments. The primary outcome is the proportion of participants achieving a significant reduction in HDV RNA and normalization of liver enzymes at week 48. Additional outcomes will be monitored up to week 120, including safety monitoring for adverse events. The total participation may last up to about two and a half years, with careful follow-up to assess long-term effects.

CONDITIONS

Brief Title

A Phase III Study to Evaluate the Efficacy and Safety of Libevitug in Participants With Chronic HDV Infection (D-clear Study)

Research Team

J

Jiaying Wen PM

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here